All Indian vaccines have to be stored at 2-8 degree Celsius: DBT secy

She said the DNA vaccine candidate being developed by Zydus Cadila, and the Biological E's mRNA vaccine work at storage temperatures of 2-8 degrees Celsius

All Indian vaccines being developed against the coronavirus will have to be stored at 2-8 degrees Celsius as the logistics have been worked out while considering temperature as a factor, Department of Biotechnology Secretary Renu Swarup said on Tuesday.

Swarup said Bharat Biotech's COVID-19 vaccine Covaxin and Oxford-AstraZeneca's Covishield have robustly undergone immunoassay lab tests.

(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, Swarup said at a press briefing.

She said the DNA vaccine candidate being developed by Zydus Cadila, and the Biological E's mRNA vaccine work at storage temperatures of 2-8 degrees Celsius.

Unlike the Pfizer and Moderna which requires a minus 70 degree Celsius (cold) chain, this (the Biological E's vaccine candidate) is basically at the 2-8 degree Celsius, Swarup said.

The Zydus Cadila candidate has been granted approval to conduct the phase-3 trial while the Biological E candidate is in its phase-1 clinical trial stage.

Swarup said Dr Reddy's Laboratories has partnered with Russia's Gamaleya Institute and a vaccine is being developed for India targeting storage at 2-8 degrees Celsius.

They (Dr Reddy's Laboratories) have started phase 2/3 trials in the country. They have completed the first part of the phase 2 trial on 1,000 subjects and they are now looking at interim data which is to be analysed.

They also have large global trials, like the Astrazeneca and that data is also being looked at. What they are targeting is for India to try and see how it could be at 2-8 degrees, Swarup said.

There are 30 vaccine candidates in India at different stages.

The country's drugs regulator Sunday granted emergency use approval to Oxford-AstraZeneca's Covishield and also to the indigenously developed Covaxin even though not enough data on the latter's efficacy and safety was available, which has triggered a debate.

Seeking to ally apprehensions on this, Swarup said, These two vaccines which have been spoken about right now, we have had the robust immunoassays which have been studied through within the laboratories.

Referring to the Translational Health Science and Technology Institute (THSTI), Faridabad, an institute under the DBT, Swarup said the lab has sets of immunoassays -- which are biochemical tests -- that run all these vaccines through them.

So anything that comes out of this immunoassay lab gives you the confidence that it has gone through the robust assay system which gives you the immunogenicity and the safety data as we move forward, Swarup said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel